Emerging mechanisms of fluoroquinolone resistance - PubMed (original) (raw)

Review

Emerging mechanisms of fluoroquinolone resistance

D C Hooper. Emerg Infect Dis. 2001 Mar-Apr.

Abstract

Broad use of fluoroquinolones has been followed by emergence of resistance, which has been due mainly to chromosomal mutations in genes encoding the subunits of the drugs' target enzymes, DNA gyrase and topoisomerase IV, and in genes that affect the expression of diffusion channels in the outer membrane and multidrug-resistance efflux systems. Resistance emerged first in species in which single mutations were sufficient to cause clinically important levels of resistance (e.g., Staphylococcus aureus and Pseudomonas aeruginosa). Subsequently, however, resistance has emerged in bacteria such as Campylobacter jejuni, Escherichia coli, and Neisseria gonorrhoeae, in which multiple mutations are required to generate clinically important resistance. In these circumstances, the additional epidemiologic factors of drug use in animals and human-to-human spread appear to have contributed. Resistance in Streptococcus pneumoniae, which is currently low, will require close monitoring as fluoroquinolones are used more extensively for treating respiratory tract infections.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Curr Opin Struct Biol. 1998 Feb;8(1):26-32 - PubMed
    1. J Infect Dis. 1997 Jun;175(6):1396-403 - PubMed
    1. Antimicrob Agents Chemother. 2000 Feb;44(2):320-5 - PubMed
    1. J Infect Dis. 1975 Jul;132(1):55-61 - PubMed
    1. FEMS Microbiol Rev. 1997 Aug;21(1):55-84 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources